title: Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
abstract: BACKGROUND
  Various treatment options exist for patients with multiple myeloma (MM). Clinical registries provide insight into routine treatment and identify changes in treatment over time.
  
  
  METHODS
  The Tumour Registry Lymphatic Neoplasms (TLN) prospectively collects data on the treatment of patients with lymphoid B cell neoplasms as administered by office-based haematologists in Germany. Data on patient and tumour characteristics, comorbidities, systemic treatments and outcome parameters are recorded.
  
  
  RESULTS
  371 non-transplant patients with MM were recruited between 2009 and 2011. At the start of first-line (second-line) treatment, the median age was 73 (75) years; 67% (74%) of the patients had stage III MM (classification of Durie and Salmon) and 19% (28%) had renal insufficiency. In the first line, 40% of the patients received bortezomib+melphalan+prednisone (VMP), 25% received bortezomib±dexamethasone (V±D) and 8% were treated with melphalan+prednisone+thalidomide (MPT). While use of bortezomib-based regimens increased from 67% (2009) to 85% (2011), use of melphalan-based regimens decreased from 68% to 48%. The overall objective response rate of treatment was 82%. In the second line, 34% of the patients received V±D and 16% lenalidomide+dexamethasone (LD).
  
  
  CONCLUSIONS
  Bortezomib-based regimens dominate the first- and second-line treatment of MM. Future analyses will investigate outcome data, e.g. effectiveness of bortezomib retherapy compared to other second-line treatments.
authors.affiliation: Onkologische Gemeinschaftspraxis, Frankfurt/M., Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Knauf
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Abenhardt
authors.forename: Ali
authors.initials: A
authors.lastname: Aldaoud
authors.forename: Arnd
authors.initials: A
authors.lastname: Nusch
authors.forename: Renate
authors.initials: R
authors.lastname: Grugel
authors.forename: Michaela
authors.initials: M
authors.lastname: Münz
authors.forename: Holger
authors.initials: H
authors.lastname: Hartmann
authors.forename: Norbert
authors.initials: N
authors.lastname: Marschner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D005938:Glucocorticoids / Q000008:administration & dosage; D006405:Hematology / Q000379:methods; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011719:Pyrazines / Q000008:administration & dosage; D012042:Registries / Q000706:statistics & numerical data*
chemical_list: D001897:Boronic Acids; D005938:Glucocorticoids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D008558:Melphalan; D011241:Prednisone